文献速递前列腺癌

新发转移性去势敏感性前列腺癌与既往局部治疗后转移复发患者的肿瘤基因表达谱差异

Differences in Tumor Gene Expression Profiles Between De Novo Metastatic Castration-sensitive Prostate Cancer and Metastatic Relapse After Prior Localized Therapy.
PubMed 文献 · Eur Urol Oncol · 2024-05-11

本研究比较了新发转移性去势敏感性前列腺癌(dn-mCSPC)与既往局部治疗后转移复发(PLT-mCSPC)患者的肿瘤基因表达谱。共纳入128例患者,Tempus队列78例用于探索,Caris队列50例用于验证。结果显示dn-mCSPC炎症通路基因表达更高,PLT-mCSPC氧化磷酸化、脂肪酸代谢和雄激素反应通路基因表达更高。

要点

  • dn-mCSPC肿瘤炎症通路基因表达高于PLT-mCSPC。
  • PLT-mCSPC肿瘤氧化磷酸化、脂肪酸代谢和雄激素反应通路基因表达更高。
  • 这些假设生成数据可能有助于指导前列腺癌个性化治疗并解释生存差异。

核心结论

  • 本研究揭示dn-mCSPC与PLT-mCSPC存在不同的基因组通路上调,这些假设生成数据可能指导前列腺癌个性化治疗并解释两者生存结局差异。

研究设计与样本

  • 纳入标准为组织学确诊前列腺腺癌且具备治疗初治原发前列腺组织的RNA测序数据。
  • RNA测序由具有临床实验室改进修正案认证的Tempus或Caris Life Sciences完成。
  • Tempus队列用于探索,Caris队列用于验证;采用DEseq2流程进行差异基因表达分析,并用基因集富集软件分析各队列富集的通路。
  • 共128例患者符合条件,Tempus队列78例(dn-mCSPC 37例,PLT-mCSPC 41例),Caris队列50例(dn-mCSPC 30例,PLT-mCSPC 20例)。

主要发现

  • dn-mCSPC患者肿瘤组织中炎症通路相关基因表达更高。
  • PLT-mCSPC患者肿瘤组织中氧化磷酸化、脂肪酸代谢和雄激素反应通路相关基因表达更高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: It has been reported that patients with de novo metastatic castration-sensitive prostate cancer (dn-mCSPC) have worse prognosis and outcomes than those whose cancer relapses after prior local therapy (PLT-mCSPC). Our aim was to interrogate and validate underlying differences in tumor gene expression profiles between dn-mCSPC and PLT-mCSPC. METHODS: The inclusion criteria were histologically confirmed prostate adenocarcinoma and the availability of RNA sequencing data for treatment-naïve primary prostate tissue. RNA sequencing was performed by Tempus or Caris Life Sciences, both of which have Clinical Laboratory Improvement Amendments certification. The Tempus cohort was used for interrogation, while the Caris cohort was used for validation. Differential gene expression analysis between the cohorts was conducted using the DEseq2 pipeline. The resulting gene expression profiles were further analyzed using Gene Set Enrichment software to identify pathways with enrichment in each cohort. KEY FINDINGS AND LIMITATIONS: Overall, 128 patients were eligible, of whom 78 were in the Tempus cohort (dn-mCSPC 37, PLT-mCSPC 41) and 50 were in the Caris cohort (dn-mCSPC 30, PLT-mCSPC 20). Tumor tissues from patients with dn-mCSPC had higher expression of genes associated with inflammation pathways, while tissues from patients with PLT-mCSPC had higher expression of genes involved in oxidative phosphorylation, fatty acid metabolism, and androgen response pathways. CONCLUSIONS AND CLINICAL IMPLICATIONS: Our study revealed upregulation of distinct genomic pathways in dn-mCSPC in comparison to PLT-mCSPC. These hypothesis-generating data could guide personalized therapy for men with prostate cancer and explain different survival outcomes for dn-mCSPC and PLT-mCSPC. PATIENT SUMMARY: We measured gene expression levels in tumors from patients with metastatic castration-sensitive prostate cancer. In patients with metastatic disease at first diagnosis, inflammatory pathways were upregulated. In patients whose metastasis occurred on relapse after treatment, androgen response pathways were upregulated. These findings could help in personalizing therapy for prostate cancer and explaining differences in survival.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Mathew Thomas V, Sayegh N, Chigarira B, et al. Differences in Tumor Gene Expression Profiles Between De Novo Metastatic Castration-sensitive Prostate Cancer and Metastatic Relapse After Prior Localized Therapy. Eur Urol Oncol. 2024. PMID: 38735779. doi:10.1016/j.euo.2024.04.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。